thioridazine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
2637 50-52-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • thioridazine
  • thioridazin
  • dl-Thioridazine
  • malloryl
  • meleril
  • thioridazine hydrochloride
  • thioridazine HCl
A phenothiazine antipsychotic used in the management of PHYCOSES, including SCHIZOPHRENIA.
  • Molecular weight: 370.57
  • Formula: C21H26N2S2
  • CLOGP: 6.20
  • LIPINSKI: 1
  • HAC: 2
  • HDO: 0
  • TPSA: 6.48
  • ALOGS: -5.64
  • ROTB: 4
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.30 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 1 mg/mL Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 35.89 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 40 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
March 15, 1962 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Overdose 50.88 35.57 26 640 101953 46583443
Coma 38.39 35.57 18 648 58331 46627065
Tachycardia 37.27 35.57 21 645 99601 46585795

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Antipsychotic drug level below therapeutic 186.99 55.00 34 1101 1338 29950005
Therapeutic product effect variable 186.57 55.00 34 1101 1355 29949988
Obsessive-compulsive disorder 182.50 55.00 40 1095 4101 29947242
Disinhibition 174.94 55.00 34 1101 1923 29949420
Euphoric mood 148.34 55.00 34 1101 4256 29947087
Increased appetite 139.22 55.00 34 1101 5583 29945760
Akathisia 137.54 55.00 34 1101 5870 29945473
Suicide attempt 89.69 55.00 38 1097 36659 29914684
Therapeutic product effect incomplete 79.21 55.00 34 1101 33800 29917543
Dyslipidaemia 75.43 55.00 21 1114 5706 29945637
Leukopenia 71.33 55.00 37 1098 56122 29895221
Obesity 71.32 55.00 22 1113 8533 29942810
Weight increased 56.22 55.00 35 1100 74878 29876465

Pharmacologic Action:

SourceCodeDescription
ATC N05AC02 NERVOUS SYSTEM
PSYCHOLEPTICS
ANTIPSYCHOTICS
Phenothiazines with piperidine structure
FDA CS M0016525 Phenothiazines
FDA EPC N0000175746 Phenothiazine
MeSH PA D014150 Antipsychotic Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D015259 Dopamine Agents
MeSH PA D018492 Dopamine Antagonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D011619 Psychotropic Drugs
MeSH PA D014149 Tranquilizing Agents
CHEBI has role CHEBI:37890 alpha-adrenoceptor antagonists
CHEBI has role CHEBI:37955 h1-receptor blockers
CHEBI has role CHEBI:48279 serotonin antagonists
CHEBI has role CHEBI:48561 dopamine blocker
CHEBI has role CHEBI:65190 typical antipsychotic drug
CHEBI has role CHEBI:76779 prolyl oligopeptidase (ec 3.4.21.26) inhibitor
CHEBI has role CHEBI:77402 trypanothione reductase inhibitors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Treatment-Resistant Schizophrenia indication
Hyperkalemia contraindication 14140009
Neuroleptic malignant syndrome contraindication 15244003 DOID:14464
Senile dementia contraindication 15662003
Orthostatic hypotension contraindication 28651003
Hypokalemia contraindication 43339004
Epilepsy contraindication 84757009 DOID:1826
Stupor contraindication 89458003
Tardive dyskinesia contraindication 102449007
Prolonged QT interval contraindication 111975006
Disease of blood AND/OR blood-forming organ contraindication 191124002 DOID:74
Coma contraindication 371632003
Breastfeeding (mother) contraindication 413712001
Congenital long QT syndrome contraindication 442917000
Predisposed to Torsades de Pointes Cardiac Arrhythmias contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.22 Basic
pKa2 3.45 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
D(2) dopamine receptor GPCR ANTAGONIST IC50 7.40 WOMBAT-PK CHEMBL
Histamine H4 receptor GPCR Ki 5.62 PDSP
Sodium-dependent dopamine transporter Transporter Ki 5.77 PDSP
5-hydroxytryptamine receptor 5A GPCR Ki 6.44 PDSP
Alpha-1B adrenergic receptor GPCR Ki 8.62 PDSP
Sodium-dependent serotonin transporter Transporter Ki 5.90 PDSP
5-hydroxytryptamine receptor 1E GPCR Ki 6.71 PDSP
5-hydroxytryptamine receptor 1B GPCR Ki 6.96 PDSP
5-hydroxytryptamine receptor 1D GPCR Ki 6.24 PDSP
Histamine H2 receptor GPCR Ki 6.87 PDSP
D(4) dopamine receptor GPCR ANTAGONIST Ki 7.98 PDSP
Muscarinic acetylcholine receptor M3 GPCR Ki 7.60 PDSP
Alpha-2C adrenergic receptor GPCR Ki 7.13 PDSP
Alpha-2B adrenergic receptor GPCR Ki 6.47 PDSP
Muscarinic acetylcholine receptor M1 GPCR Ki 8.57 PDSP
Alpha-2A adrenergic receptor GPCR Ki 6.87 PDSP
Muscarinic acetylcholine receptor M5 GPCR Ki 7.89 PDSP
Muscarinic acetylcholine receptor M4 GPCR Ki 8.05 PDSP
Muscarinic acetylcholine receptor M2 GPCR Ki 7.85 PDSP
5-hydroxytryptamine receptor 2C GPCR ANTAGONIST Ki 7.30 IUPHAR
5-hydroxytryptamine receptor 6 GPCR ANTAGONIST Ki 7.20 IUPHAR
Histamine H1 receptor GPCR ANTAGONIST Ki 7.70 IUPHAR
5-hydroxytryptamine receptor 1A GPCR ANTAGONIST Ki 7.10 IUPHAR
D(1B) dopamine receptor GPCR ANTAGONIST Ki 5.60 IUPHAR
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 6.82 DRUG MATRIX
Sodium-dependent noradrenaline transporter Transporter Ki 5.81 DRUG MATRIX
5-hydroxytryptamine receptor 2B GPCR Ki 7.09 DRUG MATRIX
Cytochrome P450 2D6 Enzyme IC50 5.75 DRUG MATRIX
Alpha-1D adrenergic receptor GPCR Ki 8.69 DRUG MATRIX
Kappa-type opioid receptor GPCR Ki 6.00 DRUG MATRIX
Cytochrome P450 1A2 Enzyme IC50 5.03 DRUG MATRIX
Epidermal growth factor receptor Kinase IC50 5.53 DRUG MATRIX
Cytochrome P450 2C19 Enzyme IC50 5.20 DRUG MATRIX
Tyrosine-protein kinase Fyn Kinase IC50 5.30 DRUG MATRIX
5-hydroxytryptamine receptor 2A GPCR ANTAGONIST EC50 8 WOMBAT-PK
Aldehyde oxidase Enzyme IC50 6.80 WOMBAT-PK
Alpha-1A adrenergic receptor GPCR IC50 7.90 WOMBAT-PK
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 7 WOMBAT-PK
D(1A) dopamine receptor GPCR IC50 7.10 WOMBAT-PK
Nuclear receptor subfamily 1 group I member 3 Nuclear hormone receptor WOMBAT-PK
Sodium channel alpha subunits; brain (Types I, II, III) Ion channel IC50 5.19 CHEMBL
Serine/threonine-protein kinase pim-1 Kinase IC50 5.16 CHEMBL
5-hydroxytryptamine receptor 7 GPCR Ki 7.15 CHEMBL
D(3) dopamine receptor GPCR ANTAGONIST IC50 7.30 WOMBAT-PK
Alpha-1B adrenergic receptor GPCR Ki 8.59 DRUG MATRIX
Membrane-associated progesterone receptor component 1 Membrane receptor Ki 6.28 DRUG MATRIX
Muscarinic acetylcholine receptor GPCR IC50 8.70 CHEMBL
Serotonin 2 (5-HT2) receptor GPCR IC50 7.74 CHEMBL
Dopamine receptor GPCR IC50 7.07 CHEMBL
Adrenergic receptor alpha-2 GPCR IC50 5.89 CHEMBL
Pleiotropic ABC efflux transporter of multiple drugs Transporter IC50 5.89 CHEMBL
Serotonin 1 (5-HT1) receptor GPCR IC50 5.06 CHEMBL
D(1A) dopamine receptor GPCR IC50 7.76 CHEMBL
Histamine H1 receptor GPCR IC50 7 CHEMBL
D(2) dopamine receptor GPCR IC50 8.55 CHEMBL
Alpha-1A adrenergic receptor GPCR IC50 8.29 CHEMBL
5-hydroxytryptamine receptor 6 GPCR ANTAGONIST Ki 8.20 IUPHAR
5-hydroxytryptamine receptor 7 GPCR ANTAGONIST Ki 7.20 IUPHAR
G protein-activated inward rectifier potassium channel 2 Ion channel GATING INHIBITOR EC50 4.20 IUPHAR

External reference:

IDSource
4019946 VUID
N0000148031 NUI
D00373 KEGG_DRUG
130-61-0 SECONDARY_CAS_RN
4017892 VANDF
4019946 VANDF
C0591768 UMLSCUI
CHEBI:9566 CHEBI
LZU PDB_CHEM_ID
CHEMBL479 ChEMBL_ID
CHEMBL1200916 ChEMBL_ID
D013881 MESH_DESCRIPTOR_UI
5452 PUBCHEM_CID
818 INN_ID
DB00679 DRUGBANK_ID
N3D6TG58NI UNII
100 IUPHAR_LIGAND_ID
10502 RXNORM
1788 MMSL
2125 MMSL
5571 MMSL
5572 MMSL
d00389 MMSL
001482 NDDF
004591 NDDF
18550006 SNOMEDCT_US
33588000 SNOMEDCT_US
372706001 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Thioridazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-0612 TABLET, FILM COATED 10 mg ORAL ANDA 15 sections
Thioridazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-0614 TABLET, FILM COATED 25 mg ORAL ANDA 15 sections
Thioridazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-0616 TABLET, FILM COATED 50 mg ORAL ANDA 15 sections
Thioridazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-0618 TABLET, FILM COATED 100 mg ORAL ANDA 15 sections
Thioridazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 51079-565 TABLET, FILM COATED 10 mg ORAL ANDA 15 sections
Thioridazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 51079-566 TABLET, FILM COATED 25 mg ORAL ANDA 15 sections
Thioridazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 51079-567 TABLET, FILM COATED 50 mg ORAL ANDA 15 sections
Thioridazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 51079-580 TABLET, FILM COATED 100 mg ORAL ANDA 15 sections
Thioridazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 53489-148 TABLET, FILM COATED 10 mg ORAL ANDA 18 sections
Thioridazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 53489-149 TABLET, FILM COATED 25 mg ORAL ANDA 18 sections
Thioridazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 53489-150 TABLET, FILM COATED 50 mg ORAL ANDA 18 sections
Thioridazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 53489-500 TABLET, FILM COATED 100 mg ORAL ANDA 18 sections
Thioridazine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 70518-1706 TABLET, FILM COATED 100 mg ORAL ANDA 15 sections